Rabbit Polyclonal CHRFAM7A Antibody

The CHRFAM7A gene, a human-specific fusion gene arising from a partial duplication of the CHRNA7 (α7 nicotinic acetylcholine receptor) gene, encodes a structurally distinct protein variant. CHRFAM7A retains exon 5-10 of CHRNA7 but replaces exons 1-4 with a duplicated segment from the FAM7A gene, resulting in a truncated protein. This unique structure impacts its function, potentially modulating α7 receptor activity or acting as an independent signaling molecule. Antibodies targeting CHRFAM7A are critical tools for studying its expression, localization, and interaction networks, particularly in neurological and immune contexts. Developing specific antibodies is challenging due to sequence homology with CHRNA7 and structural variations across isoforms. Validated antibodies enable research into CHRFAM7A's roles in neuroinflammation, schizophrenia, Alzheimer's disease, and other conditions linked to cholinergic signaling dysregulation. Emerging evidence suggests CHRFAM7A may serve as a biomarker or therapeutic target, driving demand for reliable detection reagents. However, antibody specificity must be rigorously confirmed using appropriate controls (e.g., knockout cells) given potential cross-reactivity. Commercial antibodies vary in performance across applications (WB, IHC, ICC), necessitating careful validation for experimental contexts. Ongoing research aims to clarify CHRFAM7A's pathophysiological mechanisms using these immunological tools.